HUZHOU, China, April 8, 2025 /PRNewswire/ — As a leader in the power battery industry, Tianneng continues to drive innovation in the battery market through relentless technological advancement and transformative business models. At a recent spring industry expo, the company not only showcased its comprehensive product portfolio but also demonstrated its vision as an industry pioneer, leveraging cutting-edge R&D and pioneering strategies to redefine the future of energy storage.
In response to China’s updated national standards for electric vehicles, Tianneng unveiled two dedicated battery models—6-DZF-16 and 6-DZF-20—featuring lightweight designs and higher specific energy. Enhanced by proprietary technologies, these products are engineered to precisely meet the evolving demands of vehicle manufacturers and end-users under the updated regulatory framework.
Steering attention to next-generation solutions, Tianneng debuted its groundbreaking Rock Series—the industry’s first commercially available solid-state battery. Solid-state technology, widely regarded as the holy grail of battery innovation, has become a focal point for global R&D teams due to its superior energy density, safety, and longevity. With the launch of the Rock Series, Tianneng solidifies its position as the first mover in applying solid-state batteries to the electric vehicle sector, marking a milestone in practical commercialization.
By balancing immediate market needs with futuristic technological roadmaps, Tianneng reaffirms its commitment to shaping a smarter, greener energy ecosystem. The company’s dual focus on policy-driven optimization and disruptive innovation underscores its role as both an industry anchor and a catalyst for transformative change.


Đề xuất
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
SK hynix Begins Mass Production of 192GB SOCAMM2 ‘Setting a New Standard for AI Server Memory Performance’